Research summary, original research, 2018

Predictors of patient radiation exposure during transcatheter aortic valve replacement

Goldsweig AM, Kennedy KF, Kolte D, Abbott JD, Gordon PC, Sharaf BL, et al.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2018

Read the original paper

In plain language

In 294 transcatheter aortic valve replacement (TAVR) procedures at one US hospital, heavier patients, surgical cutdown access and vascular complications were linked to higher patient radiation dose. Staff dose was not measured, though patient dose drivers often influence scatter to the team.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Patients
Size
n = 294 procedures
Where
United States
Summary based on
the abstract

What it found

  • Median patient dose-area product during TAVR was 169 Gy*cm2.

    Key figures: median dose-area product (DAP) 169 Gy*cm2 [interquartile range (IQR) 106-238]; n=294

  • Higher patient weight, cutdown transfemoral access, higher creatinine and hemoglobin, and vascular complications predicted higher DAP.

  • Regression models explained under half of DAP variance.

    Key figures: r2 0.457 (27-variable) and 0.420 (8-variable)

  • Procedure year was not a significant predictor, suggesting no learning curve effect on dose.

  • Authors suggest percutaneous femoral access may help reduce exposure.

Limits to keep in mind

Single-centre retrospective registry analysis with two operators and one imaging system; measures patient dose only, with no staff dosimetry, and models explain under half of dose variation.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.